Funded Health Care Startups in Ireland
Across the 45 Ireland-based health care startups shown, the largest disclosed round is Neurent Medical at $75M (Series C) on 2026-02-11, and it sits notabl…
Across the 45 Ireland-based health care startups shown, the largest disclosed round is Neurent Medical at $75M (Series C) on 2026-02-11, and it sits notably above the next tier of large rounds (e.g., ProVerum Medical’s $80M on 2025-08-25 is the other clear high-end deal, while many others are in the $1M–$22M band). There are also sharp low-end disclosures: the smallest disclosed amount is $220K for SAOL (Seed) on 2023-11-22, while several “undisclosed” rounds appear (5 entries: My Moves Matter, Pumpinheart, CRAOI, Latch Medical, and ATXA Therapeutics/Ostoform).
Funding activity clusters by time and geography rather than being evenly distributed: multiple rounds land in mid-2024 to early-2025 (for example, 2024-10-07 to 2025-01-08 includes Rockfield Medical Devices ($4M on 2025-12-08) and several $6M–$18M rounds in 2024-12 to 2025-01), and Dublin repeatedly anchors deals (e.g., Vertigenius on 2026-04-08, ProVerum Medical on 2025-08-25, and LaNua Medical on 2024-12-12). The date window spans 2020-09-23 (MEG Support Tools, $500K) through the most recent round on 2026-06-29 (Neurobell, $6M), with no health care entries earlier than 2020-09-23 in this view.
Most recent rounds
45 shownRelated listings
Frequently asked
What are the standout disclosed round sizes in this Ireland health care set, and how separated are they from the rest?
The largest disclosed amount is Neurent Medical’s $75M (Series C) on 2026-02-11, followed by ProVerum Medical’s $80M (Series B) on 2025-08-25, both sitting well above the typical $1M–$22M range visible in entries such as ONK Therapeutics ($22M on 2022-01-06) and Spectrum Life ($18M on 2024-05-27). At the low end, SAOL’s $220K Seed on 2023-11-22 is the smallest disclosed amount.
Are there meaningful outliers beyond size, such as grant-funded deals versus larger financings?
Yes: two entries are labeled “Grant” with undisclosed amounts on 2022-10-21 (ATXA Therapeutics and Ostoform), and those form an outlier type versus the larger disclosed financings like DeepVerge’s $33M (Post-IPO Debt) on 2022-03-19 and Amryt Pharma’s $125M (Post-IPO Debt) on 2022-02-22.
Which city appears most often, and does it coincide with the higher-dollar rounds?
Dublin is repeatedly represented across years (e.g., Vertigenius on 2026-04-08 for $3M; ProVerum Medical on 2025-08-25 for $80M; LaNua Medical on 2024-12-12 as Seed for $6M; OneProjects on 2021-10-14 for $8M), and the list also contains some of the largest disclosed rounds tied to Dublin (notably ProVerum Medical’s $80M and Amryt Pharma’s $125M on 2022-02-22).
Is there a temporal cluster near the top of the list (most recent rounds), or is activity spread out?
The 45 rows span 2020-09-23 to 2026-06-29, and several large deals cluster in the 2025–2026 window (for example, CrannMed $15M on 2026-02-26, Neurent Medical $75M on 2026-02-11, and ProVerum Medical $80M on 2025-08-25). There are also multiple Seed/early-stage entries between 2024-12 and 2025-01 (e.g., LaNua Medical Seed $6M on 2024-12-12; NUA Surgical Series A $7M on 2024-12-06; Novus Diagnostics Seed $5M on 2025-01-15).
What does the stage mix suggest—how often does the list use “Series Unknown” compared with named stages?
“Series Unknown” is frequent, appearing on many rows (e.g., Neurobell $6M on 2026-06-29; Vertigenius $3M on 2026-04-08; Bluedrop Medical $1M on 2026-02-02; CroíValve $3M on 2025-07-01), indicating a heavy share of rounds without a specified stage. Named stages and instruments still show up repeatedly, including multiple Seeds (Novus Diagnostics $5M on 2025-01-15; LaNua Medical $6M on 2024-12-12; SepTec $5M on 2022-11-21) and Post-IPO Debt (Amryt Pharma $125M on 2022-02-22; DeepVerge $33M on 2022-03-19).
Are “undisclosed” amounts common here, and which dated entries should analysts treat carefully?
Undisclosed amounts are present in 5 rows: My Moves Matter (2023-07-04), Pumpinheart (2023-06-06), CRAOI (2023-04-14), Latch Medical (2022-08-11), and the Grant-labeled pair ATXA Therapeutics and Ostoform on 2022-10-21 (both undisclosed). These should be excluded from any ‘largest/smallest disclosed’ comparisons because they are not numerically comparable to disclosed amounts like Amryt Pharma’s $125M (2022-02-22) or MEG Support Tools’ $500K (2020-09-23).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.